Payment overview · 2025
General Payments
$847.13
42 reported records · 14 companies
Healthcare provider profile · identity verified
Timothy J Snodgrass, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DALTON, GA · NPI 1962484055
Verified facts
What the public records show
CMS Open Payments records show Timothy J Snodgrass, D.O. received $847.13 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $341.07 | 40.3% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.67 | 8.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.03 | 7.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.17 | 7.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.80 | 7.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.84 | 5.5% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.02 | 5.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.91 | 4.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.99 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.05 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.61 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.88 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.11 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.98 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.13 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $311.69 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $107.22 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $72.67 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.17 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 612 | 146 |
| Lisinopril | Lisinopril | 487 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 115 |
| Gabapentin | Gabapentin | 364 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 82 |
| Metformin Hcl | Metformin Hcl | 299 | 79 |
| Omeprazole | Omeprazole | 299 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 73 |
| Meloxicam | Meloxicam | 214 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 184 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 41 |
| Trazodone Hcl | Trazodone Hcl | 167 | 45 |
| Losartan Potassium | Losartan Potassium | 166 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 35 |
| Valsartan | Valsartan | 158 | 45 |
| Famotidine | Famotidine | 153 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 27 |
| Furosemide | Furosemide | 148 | 51 |
| Potassium Chloride | Potassium Chloride | 143 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 34 |
| Alendronate Sodium | Alendronate Sodium | 141 | 34 |
| Metformin Hcl Er | Metformin Hcl | 136 | 33 |
| Eliquis | Apixaban | 129 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 29 |
| Montelukast Sodium | Montelukast Sodium | 113 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 28 |
| Carvedilol | Carvedilol | 100 | 30 |
| Sertraline Hcl | Sertraline Hcl | 100 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 22 |
| Jardiance | Empagliflozin | 84 | 23 |
| Simvastatin | Simvastatin | 84 | 25 |
| Alprazolam | Alprazolam | 76 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 19 |
| Allopurinol | Allopurinol | 74 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 71 | 16 |
| Buspirone Hcl | Buspirone Hcl | 71 | 21 |
| Ozempic | Semaglutide | 71 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 26 |
| Farxiga | Dapagliflozin Propanediol | 66 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 15 |
| Ondansetron Odt | Ondansetron | 63 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 19 |
| Tramadol Hcl | Tramadol Hcl | 60 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 22 |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Ibuprofen | Ibuprofen | 54 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 19 |
| Promethazine Hcl | Promethazine Hcl | 51 | 15 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Glimepiride | Glimepiride | 45 | 12 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 14 |
| Atenolol | Atenolol | 43 | 16 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 14 |
| Nifedipine Er | Nifedipine | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 15 |
| Estradiol | Estradiol | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 16 |
| Risperidone | Risperidone | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Glipizide | Glipizide | 39 | 12 |
| Cefuroxime | Cefuroxime Axetil | 38 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 21 |
| Linzess | Linaclotide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 15 |
| Prednisone | Prednisone | 30 | 18 |
| Topiramate | Topiramate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxaprozin | Oxaprozin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.13 · 42 records | ABBVIE INC. | Auvelity, CAPLYTA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error